- Home
- DBVT vs EMF Comparison
DBVT vs EMF Comparison
Compare DBVT & EMF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DBVT
- EMF
- Stock Information
- Founded
- DBVT 2002
- EMF 1987
- Country
- DBVT France
- EMF United States
- Employees
- DBVT N/A
- EMF N/A
- Industry
- DBVT Biotechnology: Biological Products (No Diagnostic Substances)
- EMF Finance/Investors Services
- Sector
- DBVT Health Care
- EMF Finance
- Exchange
- DBVT Nasdaq
- EMF Nasdaq
- Market Cap
- DBVT 273.6M
- EMF 219.3M
- IPO Year
- DBVT N/A
- EMF N/A
- Fundamental
- Price
- DBVT $9.66
- EMF $15.27
- Analyst Decision
- DBVT Buy
- EMF
- Analyst Count
- DBVT 4
- EMF 0
- Target Price
- DBVT $14.81
- EMF N/A
- AVG Volume (30 Days)
- DBVT 35.5K
- EMF 29.3K
- Earning Date
- DBVT 07-29-2025
- EMF 01-01-0001
- Dividend Yield
- DBVT N/A
- EMF 6.16%
- EPS Growth
- DBVT N/A
- EMF N/A
- EPS
- DBVT N/A
- EMF N/A
- Revenue
- DBVT $3,800,000.00
- EMF N/A
- Revenue This Year
- DBVT $1,743.46
- EMF N/A
- Revenue Next Year
- DBVT $1,045.66
- EMF N/A
- P/E Ratio
- DBVT N/A
- EMF N/A
- Revenue Growth
- DBVT N/A
- EMF N/A
- 52 Week Low
- DBVT $2.21
- EMF $10.58
- 52 Week High
- DBVT $12.78
- EMF $12.67
- Technical
- Relative Strength Index (RSI)
- DBVT 49.63
- EMF 55.62
- Support Level
- DBVT $8.91
- EMF $15.33
- Resistance Level
- DBVT $10.34
- EMF $15.66
- Average True Range (ATR)
- DBVT 0.54
- EMF 0.19
- MACD
- DBVT -0.03
- EMF -0.02
- Stochastic Oscillator
- DBVT 52.61
- EMF 50.00
About DBVT DBV Technologies S.A.
DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Its main product candidate under development is Viaskin Peanut for the treatment of peanut-allergic patients. In addition, the company also has earlier-stage food allergy programs, including Viaskin Milk and Eosinophilic Esophagitis, or EoE.
About EMF Templeton Emerging Markets Fund
Templeton Emerging Markets Fund is a closed-end management investment company. It seeks long-term capital appreciation by investing, under normal market conditions, at least 80% of its net assets in emerging country equity securities. It invests in various sectors such as Pharmaceuticals, Beverages, Broadline Retail, Metals &Mining, Banks, Food Products, Semiconductors & Semiconductor Equipment, insurance, Entertainment, and others.